VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
VERTEX PHARMACEUTICALS INC / MA revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $3.33B | $2.99B | $3.19B | $3.08B | $2.94B | $2.76B | $2.91B | $2.77B | $2.65B | $2.69B | – | – | 100.0% | +13.2% |
| Total CF product revenues, net | $3.21B | $2.92B | – | – | $2.90B | $2.74B | – | – | – | – | – | – | 96.2% | +10.6% |
| TRIKAFTA/KAFTRIO | $2.50B | $2.35B | $2.57B | $2.65B | $2.55B | $2.54B | $2.72B | $2.59B | $2.45B | $2.48B | $2.33B | $2.27B | 74.9% | -2.1% |
| ALYFTREK | $573.60M | $424.40M | $380.10M | $247.00M | $156.80M | $53.90M | $0 | $0 | $0 | $0 | – | – | 17.2% | +265.8% |
| Other CF product revenues | $137.10M | $135.90M | $237.40M | $175.80M | $193.70M | $155.30M | $191.20M | $186.90M | $196.40M | $207.00M | $184.40M | $209.20M | 4.1% | -29.2% |
| CASGEVY | $76.40M | $42.90M | $54.30M | $16.90M | $30.40M | $14.20M | $8.00M | $2.00M | $0 | – | – | – | 2.3% | +151.3% |
| JOURNAVX | $49.60M | $29.00M | $26.70M | $19.60M | $12.00M | $1.30M | $0 | $0 | $0 | – | – | – | 1.5% | +313.3% |
| Other revenues | $0 | $0 | $0 | $0 | $20.70M | $10.00M | $0 | $0 | $0 | $0 | – | – | 0.0% | -100.0% |
| KALYDECO | – | – | – | – | – | – | – | – | – | – | $112.40M | $112.80M | – | – |
| ORKAMBI | – | – | – | – | – | – | – | – | – | – | $44.20M | $63.00M | – | – |
| SYMDEKO/SYMKEVI | – | – | – | – | – | – | – | – | – | – | $27.80M | $33.40M | – | – |
| Other CF products | – | – | – | – | – | – | – | – | $196.40M | $207.00M | – | – | – | – |
| CASGEVY And JOURNAVX | – | – | – | – | – | $14.20M | – | – | – | $0 | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.06B | $1.78B | – | – | $1.85B | $1.66B | $1.84B | $1.71B | $1.61B | $1.52B | $1.57B | $1.55B | 61.7% | +11.3% |
| Total revenues outside of the United States | $1.28B | $1.21B | – | – | $1.12B | $1.11B | – | $1.06B | $1.03B | $1.17B | – | $929.30M | 38.3% | +14.4% |
| Europe | $977.70M | $950.00M | – | – | $910.90M | $826.60M | $832.00M | $847.70M | $806.80M | $967.40M | $735.30M | $766.50M | 29.3% | +7.3% |
| Other | $299.80M | $261.00M | – | – | $205.60M | $280.10M | – | – | – | – | – | – | 9.0% | +45.8% |
| Other | – | – | – | – | – | – | – | $210.70M | $224.50M | $203.30M | – | $162.80M | – | – |
From the segment and revenue-disaggregation notes of Vertex Pharmaceuticals Inc / Ma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.